Literature DB >> 10428752

The myth of the in situ graft: superiority in infrainguinal bypass surgery?

J A Lawson1, M J Tangelder, A Algra, B C Eikelboom.   

Abstract

OBJECTIVES: to compare the clinical outcome of in situ and reversed bypass grafting.
DESIGN: multicentre, prospective, non-randomised study. PATIENTS AND METHODS: five-hundred patients with an in situ graft and 955 patients with a reversed graft were compared regarding graft occlusion, the need for graft revision, and limb salvage.
RESULTS: two-year assisted primary patency of femoropopliteal bypass procedures was 82% for in situ and 82% for reversed grafts. The corresponding hazard ratio (HR) for occlusion was 1.27 (95% CI 0. 91-1.77). The 2-year assisted primary patency of femorocrural bypass procedures was 69% for in situ vs. 70% for reversed grafts. The corresponding HR was 1.13 (95% CI 0.73-1.75). Adjustment for relevant baseline variables did not change the results. More reinterventions were needed to maintain integrity and patency of the in situ graft especially in crural bypasses. No differences in limb salvage rates were seen.
CONCLUSIONS: reversed and in situ vein grafts have similar patency and limb salvage rates for both femoropopliteal and femorocrural bypass procedures. The in situ graft needs more secondary interventions. Copyright 1999 W.B. Saunders Company Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10428752     DOI: 10.1053/ejvs.1999.0865

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  2 in total

Review 1.  Basic data related to surgical infrainguinal revascularization procedures: a twenty year update.

Authors:  Kenneth R Ziegler; Akihito Muto; Sammy D D Eghbalieh; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2011-04       Impact factor: 1.466

Review 2.  Bypass surgery for lower extremity limb salvage: vein bypass.

Authors:  Hosam F El-Sayed
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.